IRINOTECAN-DP irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan-dp irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-GA irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan-ga irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-DP irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan-dp irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-GA irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan-ga irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irinotecan Ebewe نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

irinotecan ebewe

novartis new zealand ltd - irinotecan hydrochloride trihydrate 20 mg/ml;   - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml   excipient: lactic acid sodium hydroxide sorbitol water for injection - irinotecan ebewe is indicated for the first line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan ebewe is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN HYDROCHLORIDE INJECTION SOLUTION كندا - الإنجليزية - Health Canada

irinotecan hydrochloride injection solution

telip, llc, a subsidiary of teligent, inc. - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

IRINOTECAN TEVA إسرائيل - الإنجليزية - Ministry of Health

irinotecan teva

abic marketing ltd, israel - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan - * for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. * for the treatment of patients with small cell lung cancer.* for the treatment of patients with gastric cancer.* irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.

IRINOTECAN HYDROCHLORIDE TRIHYDRATE FOR INJECTION SOLUTION كندا - الإنجليزية - Health Canada

irinotecan hydrochloride trihydrate for injection solution

fresenius kabi canada ltd - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

IRINOTECAN HYDROCHLORIDE INJECTION, USP SOLUTION كندا - الإنجليزية - Health Canada

irinotecan hydrochloride injection, usp solution

generic medical partners inc - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

Irinotecan Actavis 100 نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

irinotecan actavis 100

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.